Market Assessment, Asthma Access and Reimbursement US 2016 Report

The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but following the recent approval of two biologics with novel mechanisms of action and with several more biologics in late-stage development for asthma, this market is set to undergo substantial change. Indeed, the influx of costly new biologics and the onset of generic competition, including biosimilars, will make prescribers’ choice of therapy and payer decisions on reimbursement more and more complex. Marketers will struggle to gain favorable formulary position and physician uptake, while health plans try to contain drug-related healthcare spend. In Asthma | Access & Reimbursement | US, we present key insights from U.S. physicians and payers on the prescribing and reimbursement of current asthma therapies, and we explore the reimbursement dynamics that promote or restrict market access of current and emerging agents.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Asthma | Access and Reimbursement | US | 2016

Related Market Assessment Reports

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Detailed, Expanded Analysis (US)

Attention-Deficit-Hyperactivity Disorder – Access & Reimbursement – Detailed, Expanded Analysis (US)

Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

Dry And Wet Age-Related Macular Degeneration – Geographic Focus-China – Dry And Wet Age-Related Macular Degeneration – China In-Depth (China)